E
EnGeneIC
Clinical-stage immuno-oncology company developing the world’s first cancer immunotherapy platform that targets tumors directly and leverages the patient’s own immune system
About EnGeneIC
EnGeneIC is an Australian biotechnology company specializing in the research, development, and manufacturing of targeted anti-cancer and anti-COVID-19 therapies. The company operates in the healthcare and biotechnology markets, focusing on innovative treatments that leverage its proprietary nanocellular technology, known as the EnGeneIC Dream Vector (EDV) platform. This platform targets tumors directly and stimulates the body's immune system to combat cancer cells and viral infections. EnGeneIC's core clients include healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around developing and licensing its technology, as well as forming strategic partnerships with major biotech firms, such as its landmark deal with ImmunityBio in the United States. Revenue is generated through licensing agreements, research collaborations, and potential future sales of its therapeutic products. The company is currently conducting clinical trials in Melbourne and plans to expand efficacy trials to the USA.
Source: Dealroom company dataAt a glance
- Founded
- 2000
- Headquarters
- Sydney, Australia
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Innovation Connections
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EnGeneIC on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EnGeneIC on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.